Search research articles
Contact Us
Filters
Showing results (81-90 of 138) with videos related to
Page
of 14
Sort By:
Nature Reviews. Clinical Oncology
|
November 2, 2024
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
Michele D Stanchina, Skye Montoya, Alexey V Danilov, et al.
Biorxiv : the Preprint Server for Biology
|
November 24, 2025
Co-targeting menin and LSD1 dismantles oncogenic programs and restores differentiation in MLL-rearranged AML
Mina M Tayari, Helena Gomes Dos Santos, Felipe Beckedorff, et al.
Leukemia
|
April 9, 2021
Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin
Kiran Batta, Hasse M Bossenbroek, Naveen Pemmaraju, et al.
Plos One
|
September 8, 2023
Human cardiovascular disease model predicts xanthine oxidase inhibitor cardiovascular risk
Ryan E Feaver, M Scott Bowers, Banumathi K Cole, et al.
Blood
|
August 5, 2022
Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy
Shivani Handa, Jeong-Ok Lee, Andriy Derkach, et al.
Leukemia & Lymphoma
|
August 25, 2025
Factors affecting treatment decisions for lower-risk myelodysplastic syndromes across practice settings
Mikkael A Sekeres, Sangeetha Venugopal, Namrata S Chandhok, et al.
NPJ Precision Oncology
|
October 19, 2022
Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
Nina Nguyen, Sana Chaudhry, Tulasigeri M Totiger, et al.
The Lancet. Haematology
|
August 1, 2020
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial
Justin Taylor, Xiaoli Mi, Alexander V Penson, et al.
Blood
|
July 9, 2020
Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms
Justin Taylor, Xiaoli Mi, Khrystyna North, et al.
Leukemia
|
October 9, 2023
E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial
Jan Philipp Bewersdorf, Maximilian Stahl, Justin Taylor, et al.
Page
of 14
Search research articles
Search
Showing results (81-90 of 138) with videos related to
Sort By:
Page
of 14
Nature Reviews. Clinical Oncology
|
November 2, 2024
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
Michele D Stanchina, Skye Montoya, Alexey V Danilov, et al.
Biorxiv : the Preprint Server for Biology
|
November 24, 2025
Co-targeting menin and LSD1 dismantles oncogenic programs and restores differentiation in MLL-rearranged AML
Mina M Tayari, Helena Gomes Dos Santos, Felipe Beckedorff, et al.
Leukemia
|
April 9, 2021
Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin
Kiran Batta, Hasse M Bossenbroek, Naveen Pemmaraju, et al.
Plos One
|
September 8, 2023
Human cardiovascular disease model predicts xanthine oxidase inhibitor cardiovascular risk
Ryan E Feaver, M Scott Bowers, Banumathi K Cole, et al.
Blood
|
August 5, 2022
Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy
Shivani Handa, Jeong-Ok Lee, Andriy Derkach, et al.
Leukemia & Lymphoma
|
August 25, 2025
Factors affecting treatment decisions for lower-risk myelodysplastic syndromes across practice settings
Mikkael A Sekeres, Sangeetha Venugopal, Namrata S Chandhok, et al.
NPJ Precision Oncology
|
October 19, 2022
Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
Nina Nguyen, Sana Chaudhry, Tulasigeri M Totiger, et al.
The Lancet. Haematology
|
August 1, 2020
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial
Justin Taylor, Xiaoli Mi, Alexander V Penson, et al.
Blood
|
July 9, 2020
Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms
Justin Taylor, Xiaoli Mi, Khrystyna North, et al.
Leukemia
|
October 9, 2023
E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial
Jan Philipp Bewersdorf, Maximilian Stahl, Justin Taylor, et al.
Page
of 14